---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-25-000090"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T05:09:52.704389+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# FDA clears IND for Centessa's ORX142, Phase 1 study in sleep-deprived volunteers planned

## Summary
- FDA cleared IND for ORX142, a novel OX2R agonist for neurological/neurodegenerative disorders.
- Phase 1 study will evaluate safety, PK, and PD (MWT, KSS) in acutely sleep-deprived healthy adults.
- Clinical data from Phase 1 expected this year; study initiation imminent.
- ORX142 is second orexin franchise candidate; ORX750 in Phase 2a for narcolepsy/IH.

## SEC filing metadata
- accession: 0001847903-25-000090
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790325000090/0001847903-25-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790325000090/cnta-20250616.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-25-000090
- JSON: https://secwatch.observer/filing/0001847903-25-000090.json
- Plain text: https://secwatch.observer/filing/0001847903-25-000090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.